Lv11
50 积分 2024-11-01 加入
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
2小时前
待确认
EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system
10天前
已完结
Post-translational modifications orchestrate the intrinsic signaling bias of GPR52
16天前
已完结
Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series
16天前
已完结
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
24天前
已完结
Tumour burden and efficacy of immune-checkpoint inhibitors
25天前
已完结
Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases
1个月前
已完结
Tuberculosis in epidermal growth factor receptor mutation in lung adenocarcinoma on treatment with gefitinib/erlotinib
1个月前
已关闭
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
3个月前
已完结
Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
5个月前
已完结
皖公网安备34019202002308
